BRPI0710185B8 - anticorpo contra receptor de fator de crescimento i semelhante à insulina - Google Patents

anticorpo contra receptor de fator de crescimento i semelhante à insulina

Info

Publication number
BRPI0710185B8
BRPI0710185B8 BRPI0710185A BRPI0710185A BRPI0710185B8 BR PI0710185 B8 BRPI0710185 B8 BR PI0710185B8 BR PI0710185 A BRPI0710185 A BR PI0710185A BR PI0710185 A BRPI0710185 A BR PI0710185A BR PI0710185 B8 BRPI0710185 B8 BR PI0710185B8
Authority
BR
Brazil
Prior art keywords
antibody
receptor
growth factor
amount
insulin
Prior art date
Application number
BRPI0710185A
Other languages
English (en)
Portuguese (pt)
Inventor
Reusch Dietmar
Kuenkele Klaus-Peter
Schumacher Ralf
Hansen Silke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0710185(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0710185A2 publication Critical patent/BRPI0710185A2/pt
Publication of BRPI0710185A8 publication Critical patent/BRPI0710185A8/pt
Publication of BRPI0710185B1 publication Critical patent/BRPI0710185B1/pt
Publication of BRPI0710185B8 publication Critical patent/BRPI0710185B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0710185A 2006-04-11 2007-04-10 anticorpo contra receptor de fator de crescimento i semelhante à insulina BRPI0710185B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06007571 2006-04-11
EP06007571.0 2006-04-11
PCT/EP2007/003165 WO2007115814A2 (en) 2006-04-11 2007-04-10 Antibodies against insulin-like growth factor i receptor and uses thereof

Publications (4)

Publication Number Publication Date
BRPI0710185A2 BRPI0710185A2 (pt) 2011-08-09
BRPI0710185A8 BRPI0710185A8 (pt) 2019-01-22
BRPI0710185B1 BRPI0710185B1 (pt) 2020-01-14
BRPI0710185B8 true BRPI0710185B8 (pt) 2021-05-25

Family

ID=36940705

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0710185A BRPI0710185B8 (pt) 2006-04-11 2007-04-10 anticorpo contra receptor de fator de crescimento i semelhante à insulina

Country Status (20)

Country Link
US (1) US20080014203A1 (enExample)
EP (2) EP2363417A1 (enExample)
JP (1) JP4718634B2 (enExample)
KR (2) KR20120028396A (enExample)
CN (1) CN101421305B (enExample)
AR (1) AR060592A1 (enExample)
AU (1) AU2007236199B2 (enExample)
BR (1) BRPI0710185B8 (enExample)
CA (2) CA3081707A1 (enExample)
CR (1) CR10301A (enExample)
EC (1) ECSP088816A (enExample)
ES (1) ES2403075T3 (enExample)
IL (1) IL194397A (enExample)
MX (1) MX2008012950A (enExample)
NO (1) NO20084082L (enExample)
NZ (1) NZ571414A (enExample)
RU (1) RU2541765C2 (enExample)
UA (1) UA95284C2 (enExample)
WO (1) WO2007115814A2 (enExample)
ZA (1) ZA200808597B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2009080278A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Stability testing of antibodies
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2010112194A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
EP2456547B2 (en) 2009-07-24 2024-03-06 F. Hoffmann-La Roche AG Stirrer system
EP2486055A4 (en) * 2009-10-07 2013-04-17 Us Health HUMAN ANTIBODIES AGAINST COMPONENTS OF THE SYSTEM OF THE HUMAN INSULINARY GROWTH FACTOR (IGF)
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
WO2012059495A1 (en) 2010-11-05 2012-05-10 F. Hoffmann-La Roche Ag Optimized method for antibody capturing by mixed mode chromatography
PL2723773T3 (pl) 2011-06-22 2018-07-31 F.Hoffmann-La Roche Ag Eliminacja komórek docelowych przez obecne w krążeniu, swoiste dla wirusa, cytotoksyczne limfocyty T z wykorzystaniem kompleksów zawierających MHC klasy I
RU2502798C2 (ru) * 2012-02-22 2013-12-27 Общество с ограниченной ответственностью "Фармако Биотех" КЛЕТОЧНАЯ ЛИНИЯ huFSHIK, СЕКРЕТИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ЧЕЛОВЕЧЕСКИЙ ФСГ
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
JP6475167B2 (ja) 2012-12-21 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2021119234A1 (en) * 2019-12-10 2021-06-17 Horizon Pharma Ireland Ltd. Glycosylated antibodies against insulin-like growth factor i receptor and uses thereof
CA3195512A1 (en) 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
JP2024531151A (ja) 2021-08-10 2024-08-29 ビリジアン セラピューティクス， インコーポレイテッド 甲状腺眼疾患の処置のための組成物、用量および方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5650508A (en) * 1991-12-27 1997-07-22 Georgia Tech Research Corporation Peptide ketoamides
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
EP2275540B1 (en) * 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
MXPA04011624A (es) * 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
CA2519113C (en) * 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
US20070142627A1 (en) * 2003-08-01 2007-06-21 Chugai Seiyaku Kabushiki Kaisha Sugar-chain-altered anti-hm1.24 antibody
EP1693069B1 (en) * 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Remedy for solid tumor

Also Published As

Publication number Publication date
BRPI0710185B1 (pt) 2020-01-14
BRPI0710185A2 (pt) 2011-08-09
NZ571414A (en) 2011-12-22
CA3081707A1 (en) 2007-10-18
US20080014203A1 (en) 2008-01-17
IL194397A (en) 2014-04-30
RU2008144290A (ru) 2010-05-20
AU2007236199A1 (en) 2007-10-18
EP2007810B1 (en) 2013-02-13
CA2647181A1 (en) 2007-10-18
RU2541765C2 (ru) 2015-02-20
CA2647181C (en) 2020-08-11
KR20120028396A (ko) 2012-03-22
WO2007115814A3 (en) 2008-01-10
AU2007236199B2 (en) 2013-07-25
EP2363417A1 (en) 2011-09-07
BRPI0710185A8 (pt) 2019-01-22
JP2009533367A (ja) 2009-09-17
MX2008012950A (es) 2008-10-15
UA95284C2 (ru) 2011-07-25
KR20080113233A (ko) 2008-12-29
ZA200808597B (en) 2009-11-25
ES2403075T3 (es) 2013-05-13
CN101421305A (zh) 2009-04-29
WO2007115814A2 (en) 2007-10-18
IL194397A0 (en) 2011-08-01
NO20084082L (no) 2008-11-06
AR060592A1 (es) 2008-07-02
JP4718634B2 (ja) 2011-07-06
CN101421305B (zh) 2013-05-15
EP2007810A2 (en) 2008-12-31
KR101276513B1 (ko) 2013-06-21
ECSP088816A (es) 2008-11-27
CR10301A (es) 2008-10-29

Similar Documents

Publication Publication Date Title
BRPI0710185A8 (pt) anticorpos contra receptor de fator de crescimento i semelhante à insulina e usos dos mesmos
BRPI0709960B8 (pt) anticorpo monoclonal do tipo igg1 ou igg3 humana glicosilado, seu uso e método de produção e composição farmacêutica
O'Donnell et al. A calcineurin-dependent switch controls the trafficking function of α-arrestin Aly1/Art6
MA27707A1 (fr) Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme
Schoeder et al. Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18
BRPI0815331B8 (pt) composição farmacêutica compreendendo um derivado de benzeno glicopiranosil-substituído, bem como seu uso
BRPI0515554A (pt) anticorpos anti-ox40l
BRPI0606992A2 (pt) análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
BRPI0517273B8 (pt) composição contendo uma mistura de três bactérias probióticas, uso desta para a prevenção e/ou tratamento de infecções do trato respiratório superior e na regularização da funcionalidade intestinal do organismo acometido por essas patologias e kit contendo uma mistura de três bactérias probióticas
BRPI0820535B8 (pt) composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
BR112012025861A2 (pt) elemento de conexão de reservatório de fármaco codificado com elementos de travamento encurváveis
BRPI0619188B8 (pt) prótese de mão
BR112013020537A2 (pt) suspensão aquosa e pó de liberação prolongada que compreendem metilfenidato
BR112022013720A2 (pt) Mutante fimh, composições com o mesmo e seu uso
BRPI0715198A8 (pt) Composição de perfume, seu uso, método e artigo adequado para prevenção ou alívio de mau odor da urina, e produtos para consumidores
CO6561811A2 (es) Composiciones de etanol
BR102017016334A8 (pt) Produto de condensação de 1-amino-2-propanol e formaldeído e o uso do mesmo para a redução da quantidade de sulfeto de hidrogênio em líquidos e gases
BRPI0502228A (pt) forma cristalina alfa de ranelato de estrÈncio, processo para sua preparação, e composições farmacêuticas que a contêm
BR112015014092A2 (pt) administração oral transmucosal de acetato de glatirâmer
BR112012014564A2 (pt) "método de combate e controle de pragas"
BRPI0609401A8 (pt) método para tratar ou prevenir inflamação sistêmica em bebês alimentados com fórmula.
BR112014009273A2 (pt) espelho
AR053691A1 (es) Agentes endoparasiticidas
BR112012031470A2 (pt) antagonistas de ciclo-hexil-azetidinila de ccr2
BRPI0600710A (pt) veìculo e composição de revelador

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/04/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF